Janux Therapeutics, Inc.
Moat Score — Janux Therapeutics, Inc.
Total Moat Score
5 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Janux's TRACTr/TRACIr/ARM masked-bispecific platform is proprietary engineering IP, and its real-world value has been validated twice over by large pharma: Merck licensed two targets for $8M upfront each plus up to $285M in milestones per target, and Bristol Myers Squibb paid $15M upfront with up to $785M in potential milestones for a single undisclosed program. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a clinical-stage biopharmaceutical company with no approved product, Janux has no manufacturing or distribution cost edge over competitors; it bears the same expensive, capital-intensive clinical development cost structure as every other biologics developer chasing these targets. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | With no approved product, Janux has no current pricing power; any future pricing power in metastatic castration-resistant prostate cancer or EGFR-driven solid tumors would depend entirely on JANX007 or JANX008 demonstrating a clear efficacy or safety edge over already-approved and in-development competitors. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no mechanism by which Janux's therapies become more valuable as more patients or physicians use them — each treatment is an independent clinical and commercial event with no platform or data network dynamic. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 0 / 5 | With no marketed product yet, there is no installed base of prescribers or patients to create switching costs; any future stickiness would have to be earned through demonstrated clinical superiority in head-to-head use rather than any built-in lock-in. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 0 / 5 | The PSMA, EGFR, CD28, and CD19 target fields Janux is pursuing are each already crowded with well-funded large-pharma competitors (AbbVie, Amgen, Regeneron, Roche, Novartis among others), so there is no sign the market naturally supports only a handful of players at efficient scale. |